topotecan + pasireotide

Topotecan + pasireotide is a combination of two pharmaceutical agents used primarily in oncology and endocrinology research. Topotecan is a semi-synthetic derivative of camptothecin and acts as an antineoplastic agent by inhibiting the enzyme DNA topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing cancer cells[8]. It is approved for the treatment of ovarian cancer, small cell lung cancer, and cervical cancer (often in combination with cisplatin)[2][4][5][8]. Pasireotide is a somatostatin analog that binds with high affinity to four somatostatin receptor subtypes (SSTR1, SSTR2, SSTR3, SSTR5), with particularly strong binding to SSTR5[1][6]. This broad receptor activity makes it effective for conditions like Cushing’s disease where pituitary tumors overexpress these receptors[1][6]. The combination may be explored experimentally for synergistic effects in certain cancers or endocrine-related tumors.

Brand names

HycamtinSignifor

Other names

topotecan hydrochlorideSOM230SOM-230SOM 230